• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

U.S. likely to miss July 4 COVID-19 vaccine target, White House says

firstwordpharmaJune 23, 2021

Tag: COVID-19 , Vaccine , White House

The US will likely fail to meet President Joe Biden's goal to deliver at least one COVID-19 vaccine to 70% of adults by July 4, as reported This is Money on Tuesday.

U.S. likely to miss July 4 COVID-19 vaccine target, White House says

Officials said the administration will likely to meet the target for adults 27 and older on July 4.

"Our focus from the beginning has been continuing to redouble our efforts among demographics and groups where we need extra assistance," said White House press secretary Jen Psaki.

White House COVID-19 senior adviser Jeffrey Zients said it would probably take a few weeks beyond July 4 to meet Biden's target.

Previous:LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

Next:Biopharmaceutical CEO Brussel meeting with EU leaders focuses on equitable access to tackle COVID-19, fostering innovation and unmet needs

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

U.S. likely to miss July 4 COVID-19 vaccine target, White House says | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard
Hualan Influenza Vaccine

Hualan Influenza Vaccine
Influenza Vaccine(Split Virion),Inactivated with good safety

Influenza Vaccine(Split Virion),Inactivated with good safety
hualan-trivalent flu vaccine

hualan-trivalent flu vaccine
Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality
Influenza Vaccine(Split Virion),Inactivated

Influenza Vaccine(Split Virion),Inactivated
High-quality Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with High purity and g

High-quality Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with High purity and g
20ml plastic vaccine bottle

20ml plastic vaccine bottle
2024-2025 quadrivalent/trivalent flu vaccine

2024-2025 quadrivalent/trivalent flu vaccine
Hualan BIO Influenza Vaccine (Split virion)

Hualan BIO Influenza Vaccine (Split virion)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service